Qiagen NV
QGEN48.560USD
+1.340+2.84%
종가 11/25, 16:00（ET）시세는 15분 지연됩니다
10.53B시가총액
25.98P/E TTM
자세한 내용은 Qiagen NV 회사
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Qiagen NV 정보
종목 코드 QGEN
회사 이름Qiagen NV
상장일Sep 01, 1996
CEOMr. Thierry Bernard
직원 수5765
유형Ordinary Share
회계 연도 종료Sep 01
주소Hulsterweg 82
도시VENLO
증권 거래소NYSE Consolidated
국가Netherlands
우편 번호5912 PL
전화31773556600
웹사이트https://www.qiagen.com/
종목 코드 QGEN
상장일Sep 01, 1996
CEOMr. Thierry Bernard
Qiagen NV의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Roland Sackers
Mr. Roland Sackers
Managing Director, Chief Financial Officer, Member of the Executive Board
Managing Director, Chief Financial Officer, Member of the Executive Board
383.09K
+59.93%
Mr. Thierry Bernard
Mr. Thierry Bernard
Chief Executive Officer, Managing Director, Member of the Executive Board
Chief Executive Officer, Managing Director, Member of the Executive Board
312.13K
+75.76%
Dr. Metin Colpan, Ph.D.
Dr. Metin Colpan, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
171.79K
-57.00%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
47.22K
+10.37%
Prof. Dr. Ross L. Levine, M.D.
Prof. Dr. Ross L. Levine, M.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
16.27K
+30.83%
Prof. Dr. Elaine R. Mardis, Ph.D.
Prof. Dr. Elaine R. Mardis, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
3.97K
--
Mr. Stephen H. (Steve) Rusckowski
Mr. Stephen H. (Steve) Rusckowski
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
24.00
--
Ms. Eva van Pelt
Ms. Eva van Pelt
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Dr. Toralf Haag, Ph.D.
Dr. Toralf Haag, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Mr. Bert van Meurs
Mr. Bert van Meurs
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Roland Sackers
Mr. Roland Sackers
Managing Director, Chief Financial Officer, Member of the Executive Board
Managing Director, Chief Financial Officer, Member of the Executive Board
383.09K
+59.93%
Mr. Thierry Bernard
Mr. Thierry Bernard
Chief Executive Officer, Managing Director, Member of the Executive Board
Chief Executive Officer, Managing Director, Member of the Executive Board
312.13K
+75.76%
Dr. Metin Colpan, Ph.D.
Dr. Metin Colpan, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
171.79K
-57.00%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
47.22K
+10.37%
Prof. Dr. Ross L. Levine, M.D.
Prof. Dr. Ross L. Levine, M.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
16.27K
+30.83%
Prof. Dr. Elaine R. Mardis, Ph.D.
Prof. Dr. Elaine R. Mardis, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
3.97K
--
수익 분석
통화: USD마지막 업데이트: Mon, Oct 6
통화: USD마지막 업데이트: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
사업별USD
이름
수익
비율
Consumables and Related Revenues
476.33M
89.28%
Instrumentation
57.21M
10.72%
지역별USD
이름
수익
비율
United States
260.49M
48.82%
Europe & Middle East & Africa
179.30M
33.61%
Asia, Pacific & Rest of the World
73.46M
13.77%
Other Americas
20.29M
3.80%
사업별
지역별
사업별USD
이름
수익
비율
Consumables and Related Revenues
476.33M
89.28%
Instrumentation
57.21M
10.72%
주식 보유 통계
마지막 업데이트: Mon, Nov 17
마지막 업데이트: Mon, Nov 17
주주
주주 유형
주주
주주
비율
Wellington Management Company, LLP
10.76%
MFS Investment Management
10.56%
The Vanguard Group, Inc.
4.30%
T. Rowe Price International Ltd
3.47%
DWS Investment GmbH
2.13%
기타
68.78%
주주
주주
비율
Wellington Management Company, LLP
10.76%
MFS Investment Management
10.56%
The Vanguard Group, Inc.
4.30%
T. Rowe Price International Ltd
3.47%
DWS Investment GmbH
2.13%
기타
68.78%
주주 유형
주주
비율
Investment Advisor/Hedge Fund
48.71%
Investment Advisor
25.43%
Research Firm
5.08%
Pension Fund
1.63%
Sovereign Wealth Fund
1.60%
Hedge Fund
1.10%
Bank and Trust
1.09%
Individual Investor
0.44%
Insurance Company
0.05%
기타
14.86%
기관 주식 보유
마지막 업데이트: Wed, Oct 1
마지막 업데이트: Wed, Oct 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q3
996
177.81M
82.00%
-32.33M
2025Q2
996
189.55M
87.53%
+6.64M
2025Q1
1017
179.03M
82.67%
+27.58M
2024Q4
1010
129.03M
59.70%
-70.06M
2024Q3
1010
183.22M
84.72%
-23.62M
2024Q2
1002
184.34M
84.75%
+8.40M
2024Q1
988
165.20M
76.61%
-7.18M
2023Q4
993
165.11M
76.72%
-10.52M
2023Q3
987
159.93M
74.32%
-12.21M
2023Q2
996
162.43M
75.49%
-6.05M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Wellington Management Company, LLP
26.02M
12%
+1.59M
+6.49%
Jun 30, 2025
MFS Investment Management
23.48M
10.83%
-787.04K
-3.24%
Jun 30, 2025
The Vanguard Group, Inc.
9.16M
4.22%
+372.54K
+4.24%
Jun 30, 2025
T. Rowe Price International Ltd
5.94M
2.74%
+1.79M
+43.10%
Jun 30, 2025
DWS Investment GmbH
3.30M
1.52%
+2.74M
+482.72%
Jun 30, 2025
EARNEST Partners, LLC
4.20M
1.94%
+395.58K
+10.39%
Jun 30, 2025
Amundi Asset Management, SAS
3.98M
1.83%
-217.72K
-5.19%
Jun 30, 2025
Boston Partners
2.36M
1.09%
+13.48K
+0.58%
Aug 31, 2025
BlackRock Institutional Trust Company, N.A.
20.54M
9.47%
+174.28K
+0.86%
Sep 10, 2025
더 보기
관련 ETF
마지막 업데이트: Thu, Nov 6
마지막 업데이트: Thu, Nov 6
이름
비율
First Trust Nasdaq Lux Digi Health Solutions ETF
3.85%
Global X Genomics & Biotechnology ETF
3.76%
Invesco Biotechnology & Genome ETF
2.45%
VanEck Biotech ETF
1.81%
ROBO Global Healthcare Technology & Innovation ETF
1.46%
Pacer US Large Cap Cash Cows Growth Leaders ETF
1.18%
Franklin Genomic Advancements ETF
1%
iShares Health Innovation Active ETF
0.93%
Burney US Factor Rotation ETF
0.75%
WisdomTree International Multifactor Fund
0.68%
더 보기
First Trust Nasdaq Lux Digi Health Solutions ETF
비율3.85%
Global X Genomics & Biotechnology ETF
비율3.76%
Invesco Biotechnology & Genome ETF
비율2.45%
VanEck Biotech ETF
비율1.81%
ROBO Global Healthcare Technology & Innovation ETF
비율1.46%
Pacer US Large Cap Cash Cows Growth Leaders ETF
비율1.18%
Franklin Genomic Advancements ETF
비율1%
iShares Health Innovation Active ETF
비율0.93%
Burney US Factor Rotation ETF
비율0.75%
WisdomTree International Multifactor Fund
비율0.68%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 18, 2024
Merger
25→24.25
Jan 18, 2024
Merger
25→24.25
날짜
유형
비율
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 18, 2024
Merger
25→24.25
Jan 18, 2024
Merger
25→24.25
Jan 18, 2024
Merger
25→24.25
Jan 18, 2024
Merger
25→24.25
자주 묻는 질문
Qiagen NV의 상위 5대 주주는 누구인가요?
Qiagen NV의 상위 5대 주주는 다음과 같습니다:
Wellington Management Company, LLP는 26.02M주의 주식을 보유하고 있으며, 전체 주식의 12.00%를 차지합니다.
MFS Investment Management는 23.48M주의 주식을 보유하고 있으며, 전체 주식의 10.83%를 차지합니다.
The Vanguard Group, Inc.는 9.16M주의 주식을 보유하고 있으며, 전체 주식의 4.22%를 차지합니다.
T. Rowe Price International Ltd는 5.94M주의 주식을 보유하고 있으며, 전체 주식의 2.74%를 차지합니다.
DWS Investment GmbH는 3.30M주의 주식을 보유하고 있으며, 전체 주식의 1.52%를 차지합니다.
Wellington Management Company, LLP는 26.02M주의 주식을 보유하고 있으며, 전체 주식의 12.00%를 차지합니다.
MFS Investment Management는 23.48M주의 주식을 보유하고 있으며, 전체 주식의 10.83%를 차지합니다.
The Vanguard Group, Inc.는 9.16M주의 주식을 보유하고 있으며, 전체 주식의 4.22%를 차지합니다.
T. Rowe Price International Ltd는 5.94M주의 주식을 보유하고 있으며, 전체 주식의 2.74%를 차지합니다.
DWS Investment GmbH는 3.30M주의 주식을 보유하고 있으며, 전체 주식의 1.52%를 차지합니다.
Qiagen NV의 상위 3대 주주 유형은 무엇인가요?
Qiagen NV의 주요 주주 유형 상위 3가지는
Wellington Management Company, LLP
MFS Investment Management
The Vanguard Group, Inc.입니다.
Wellington Management Company, LLP
MFS Investment Management
The Vanguard Group, Inc.입니다.
Qiagen NV(QGEN)의 주식을 보유한 기관은 몇 개입니까?
2025Q3 기준으로, Qiagen NV의 주식을 보유한 기관은 총 996곳이며, 이들이 보유한 주식의 총 가치는 약 177.81M로 전체 발행 주식의 82.00%를 차지합니다. 이는 2025Q2 대비 -5.53% 증가한 수치입니다.
Qiagen NV의 최대 수익원은 무엇인가요?
FY2025Q2 기준, Qiagen NV의 Consumables and Related Revenues 부문이 가장 높은 매출을 기록했으며, 금액은 476.33M로 전체 매출의 89.28%를 차지했습니다.
